Malignancies associated with GIST: a retrospective study with molecular analysis of KIT and PDGFRA.
Aged
Aged, 80 and over
Female
Gastrointestinal Neoplasms
/ genetics
Gastrointestinal Stromal Tumors
/ genetics
Humans
Male
Middle Aged
Mutation
/ genetics
Neoplasms, Second Primary
/ genetics
Proto-Oncogene Proteins c-kit
/ genetics
Receptor, Platelet-Derived Growth Factor alpha
/ genetics
Retrospective Studies
Additional/secondary malignancy
GIST
Gastrointestinal stromal tumor
KIT
Mutation
PDGFRA
Journal
Langenbeck's archives of surgery
ISSN: 1435-2451
Titre abrégé: Langenbecks Arch Surg
Pays: Germany
ID NLM: 9808285
Informations de publication
Date de publication:
Aug 2019
Aug 2019
Historique:
received:
23
08
2018
accepted:
27
02
2019
pubmed:
17
3
2019
medline:
13
2
2020
entrez:
17
3
2019
Statut:
ppublish
Résumé
Gastrointestinal stromal tumors (GISTs) are the most common soft tissue tumors of the GI tract. Studies have been published reporting additional neoplasms in GIST patients. This study aimed to evaluate possible associations of mutation type, morphology, and clinical aspects of GISTs. All cases of GIST were identified from our pathology files. Coding exons of KIT and PDGFRA in GISTs with additional malignancies were sequenced. A total of 70 of 188 (37%) retrieved patients with confirmed diagnosis of GIST showed at least one additional malignant neoplasm. Fifty of these GISTs were located in the stomach (71%), 8 in the small intestine (11%), 5 in the colon/rectum (7%), and 7 cases (6.2%) were of undetermined sites of origin. The distribution of identified mutations was similar to that described in GISTs without secondary malignancies. A total of 37 of 57 cases (65%) showed mutations in the KIT gene exon 11, 3 (5%) cases in exon 9, and 1 (2%) case in exon 13. Nine tumors (16%) had mutations of the PDGFRA gene. KIT and PDGFRA wild-type status were found in seven cases (12%). Most of the secondary neoplasms were located within the GI tract (34%), in the urogenital system (24%), or the breast/female genital tract (20%). This study confirms the high rate of additional malignant tumors in GIST patients. GIST features in these cases are very similar to those with sole GIST.
Identifiants
pubmed: 30877378
doi: 10.1007/s00423-019-01773-2
pii: 10.1007/s00423-019-01773-2
doi:
Substances chimiques
KIT protein, human
EC 2.7.10.1
Proto-Oncogene Proteins c-kit
EC 2.7.10.1
Receptor, Platelet-Derived Growth Factor alpha
EC 2.7.10.1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
605-613Références
Am J Surg Pathol. 2005 Jan;29(1):52-68
pubmed: 15613856
Cancer. 2005 Feb 15;103(4):821-9
pubmed: 15648083
Am J Gastroenterol. 2005 Jan;100(1):162-8
pubmed: 15654796
Arch Pathol Lab Med. 2006 Oct;130(10):1466-78
pubmed: 17090188
Semin Diagn Pathol. 2006 May;23(2):120-9
pubmed: 17193825
Ann Oncol. 2010 Oct;21(10):2107-11
pubmed: 20348145
Surg Oncol. 2010 Dec;19(4):e140-3
pubmed: 20675121
Ann Oncol. 2012 May;23(5):1335-40
pubmed: 21994214
Nat Rev Cancer. 2011 Nov 17;11(12):865-78
pubmed: 22089421
Clin Cancer Res. 2012 Mar 15;18(6):1769-76
pubmed: 22282465
Clin Epidemiol. 2013 May 16;5:147-62
pubmed: 23700373
Int J Surg. 2014;12(5):371-7
pubmed: 24632413
Cancer. 2014 Aug 1;120(15):2325-33
pubmed: 24737415
Ann Surg Oncol. 2015 Aug;22(8):2633-9
pubmed: 25564173
Neoplasia. 2015 Jan;17(1):134-40
pubmed: 25622906
World J Surg Oncol. 2015 Feb 13;13:47
pubmed: 25885906
Cancer. 2015 Sep 1;121(17):2960-7
pubmed: 25930983
Int J Cancer. 2016 Oct 15;139(8):1744-51
pubmed: 27299364
Medicine (Baltimore). 2016 Sep;95(38):e4718
pubmed: 27661019
Dig Dis. 2018;36(5):337-345
pubmed: 29870973
J Surg Oncol. 2018 Jun;117(8):1716-1720
pubmed: 29878354
Clin Transl Oncol. 2019 May;21(5):646-655
pubmed: 30368726
Science. 1998 Jan 23;279(5350):577-80
pubmed: 9438854